GSK plc(GSK)Earnings, Financials & Key Ratios
GSK•NYSE
6.9× P/E·Price updated Jun 19, 2026
AboutGSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development; two strategic collaborations with Relation to advance therapeutics for fibrotic diseases and osteoarthritis; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.dom.Show more
- Revenue$32.67B+4.1%
- EBITDA$10.65B+62.1%
- Net Income$5.72B+122.0%
- EPS (Diluted)5.56+348.4%
- Gross Margin72.4%+1.7%
- EBITDA Margin32.61%+55.7%
- Operating Margin25.52%+99.2%
- Net Margin17.5%+113.2%
- ROE39.4%+124.9%
GSK Key Insights
GSK plc (GSK) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Excellent 3Y average ROE of 31.4%
- ✓Strong Piotroski F-Score: 8/9
- ✓FCF machine: 17.8% free cash flow margin
- ✓High quality earnings: Operating CF exceeds net income
- ✓Share count reduced 50.3% through buybacks
- ✓Healthy 5Y average net margin of 22.1%
✗Weaknesses
No significant weaknesses identified
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when GSK posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
GSK Price & Volume
GSK plc (GSK) stock price & volume — 10-year historical chart
Loading chart...
GSK Growth Metrics
GSK plc (GSK) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years3.16%
5 Years6.05%
3 Years3.66%
TTM5.41%
Profit CAGR
10 Years-3.8%
5 Years-0.12%
3 Years-27.43%
TTM86.94%
EPS CAGR
10 Years2.6%
5 Years14.22%
3 Years32.32%
TTM120.34%
Return on Capital
10 Years11.92%
5 Years12.74%
3 Years15.54%
Last Year21.54%
GSK Recent Earnings
GSK plc (GSK) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 10/12 qtrs (91%)●Beat Revenue 10/12 qtrs (91%)
Q2 2026Latest
Apr 29, 2026Metric
Actual
Est
EPS
$1.24+6.9%
$1.16
Rev
$10.3B+0.7%
$10.2B
Q1 2026
Feb 4, 2026Metric
Actual
Est
EPS
$0.68+6.3%
$0.64
Rev
$11.8B+3.2%
$11.4B
Q4 2025
Oct 29, 2025Metric
Actual
Est
EPS
$1.48+17.5%
$1.26
Rev
$8.5B+0.8%
$8.5B
Q3 2025
Jul 30, 2025Metric
Actual
Est
EPS
$0.96
—
Rev
$10.9B
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 29, 2026 | $1.24vs $1.16+6.9% | $10.3Bvs $10.2B+0.7% |
| Q1 2026 | Feb 4, 2026 | $0.68vs $0.64+6.3% | $11.8Bvs $11.4B+3.2% |
| Q4 2025 | Oct 29, 2025 | $1.48vs $1.26+17.5% | $8.5Bvs $8.5B+0.8% |
| Q3 2025 | Jul 30, 2025 | $0.96 | $10.9B |
Based on last 12 quarters of dataView full earnings history →
GSK Peer Comparison
GSK plc (GSK) competitors in Vaccines and plasma-derived therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 AZN | 271.19B | 174.93 | 26.75 | 8.63% | 17.19% | 22.24% | 0.61 | |
 NVS | 280.64B | 147.08 | 20.46 | 5.97% | 24.14% | 31.42% | 0.80 | |
 SNY | 102.35B | 42.38 | 18.14 | 5.49% | 16.72% | 10.78% | 0.30 | |
 PFE | 143.46B | 25.22 | 18.54 | -1.65% | 11.83% | 8.34% | 0.78 | |
 MRK | 281.25B | 113.87 | 15.64 | 1.18% | 28.12% | 36.14% | 0.96 | |
 BMY | 110.25B | 54.00 | 15.65 | -0.22% | 15.01% | 38.96% | 2.55 | |
 LLY | 1.04T | 1098.13 | 47.85 | 44.7% | 34.98% | 101.17% | 1.60 | |
 ABBV | 383.17B | 216.63 | 91.41 | 8.57% | 6.91% | 62.15% |
Compare GSK vs Peers
GSK plc (GSK) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
GSK Income Statement
GSK plc (GSK) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 30.19B | 30.82B | 33.75B | 24.35B | 24.7B | 29.32B | 30.33B | 31.38B | 32.67B | 33.34B |
Revenue Growth % | 8.24% | 2.1% | 9.52% | -27.85% | 1.4% | 18.74% | 3.42% | 3.46% | 4.11% | 5.41% |
Cost of Goods Sold | 10.34B | 10.24B | 11.86B | 7.93B | 8.16B | 9.55B | 8.56B | 9.05B | 9.02B | 8.96B |
COGS % of Revenue | 34.26% | 33.23% | 35.15% | 32.56% | 33.05% | 32.58% | 28.24% | 28.84% | 27.6% | - |
Gross Profit | 19.84B▲ 0% | 20.58B▲ 3.7% | 21.89B▲ 6.4% | 16.43B▼ 25.0% | 16.53B▲ 0.7% | 19.77B▲ 19.6% | 21.76B▲ 10.1% | 22.33B▲ 2.6% | 23.65B▲ 5.9% | 24.29B▲ 0% |
Gross Margin % | 65.74% | 66.77% | 64.85% | 67.44% | 66.95% | 67.42% | 71.76% | 71.16% | 72.4% | 72.86% |
Gross Profit Growth % | 6.69% | 3.71% | 6.37% | -24.97% | 0.66% | 19.58% | 10.08% | 2.6% | 5.92% | - |
Operating Expenses | 15.76B | 15.1B | 14.93B | 10.45B | 12.18B | 13.34B | 15.02B | 18.31B | 15.31B | 15.41B |
OpEx % of Revenue | 52.2% | 48.98% | 44.23% | 42.89% | 49.3% | 45.48% | 49.52% | 58.35% | 46.87% | - |
Selling, General & Admin | 9.67B | 9.91B | 11.4B | 7.44B | 7.07B | 8.37B | 9.38B | 11.02B | 9.09B | 9.14B |
SG&A % of Revenue | 32.04% | 32.17% | 33.78% | 30.54% | 28.63% | 28.55% | 30.95% | 35.11% | 27.82% | - |
Research & Development | 4.48B | 3.89B | 4.57B | 4.79B | 5.02B | 5.49B | 6.22B | 6.4B | 7.53B | 7.75B |
R&D % of Revenue | 14.83% | 12.63% | 13.53% | 19.68% | 20.32% | 18.71% | 20.52% | 20.4% | 23.04% | - |
Other Operating Expenses | 1.61B | 1.29B | -1.04B | -1.78B | 87M | -523M | -590M | 891M | -1.3B | -4M |
Operating Income | 4.09B▲ 0% | 5.48B▲ 34.2% | 6.96B▲ 27.0% | 5.98B▼ 14.1% | 4.36B▼ 27.1% | 6.43B▲ 47.6% | 6.75B▲ 4.8% | 4.02B▼ 40.4% | 8.34B▲ 107.4% | 8.98B▲ 0% |
Operating Margin % | 13.54% | 17.79% | 20.62% | 24.55% | 17.64% | 21.94% | 22.24% | 12.82% | 25.52% | 26.95% |
Operating Income Growth % | 57.31% | 34.16% | 26.96% | -14.11% | -27.13% | 47.65% | 4.85% | -40.39% | 107.36% | - |
EBITDA | 6.01B | 7.34B | 9.08B | 8.03B | 6.48B | 8.58B | 9.04B | 6.57B | 10.65B | 11.71B |
EBITDA Margin % | 19.91% | 23.81% | 26.9% | 32.97% | 26.24% | 29.26% | 29.8% | 20.95% | 32.61% | 35.11% |
EBITDA Growth % | 37.44% | 22.13% | 23.74% | -11.58% | -19.3% | 32.43% | 5.35% | -27.29% | 62.08% | 38.23% |
D&A (Non-Cash Add-back) | 1.92B | 1.86B | 2.12B | 2.05B | 2.12B | 2.15B | 2.29B | 2.55B | 2.31B | 3.14B |
EBIT | 4.26B | 5.49B | 7.1B | 6.02B | 4.36B | 6.45B | 6.79B | 4.12B | 8.09B | 8.13B |
Net Interest Income | -667M | -665.8M | -810.89M | -852M | -755M | -791.26M | -735M | -590.19M | -631M | -601M |
Interest Income | 65M | 77.83M | 98M | 44M | 28M | 64.27M | 40M | 67.39M | 56M | 98M |
Interest Expense | 734M | 743.64M | 912M | 892M | 784M | 855.53M | 775M | 657.58M | 687M | 692M |
Other Income/Expense | -562M | -683M | -740M | -809M | -758M | -805M | -681M | -544M | -937M | -978M |
Pretax Income | 3.52B▲ 0% | 4.8B▲ 36.2% | 6.22B▲ 29.6% | 5.17B▼ 16.9% | 3.6B▼ 30.4% | 5.63B▲ 56.4% | 6.06B▲ 7.7% | 3.48B▼ 42.7% | 7.4B▲ 112.9% | 7.44B▲ 0% |
Pretax Margin % | 11.68% | 15.57% | 18.43% | 21.23% | 14.57% | 19.19% | 19.99% | 11.08% | 22.66% | 22.31% |
Income Tax | 1.36B | 754M | 953M | 67M | 83M | 707M | 756M | 526M | 1.11B | 1.08B |
Effective Tax Rate % | 38.47% | 15.71% | 15.32% | 1.3% | 2.31% | 12.56% | 12.47% | 15.13% | 15.02% | 14.54% |
Net Income | 1.53B▲ 0% | 3.62B▲ 136.5% | 4.64B▲ 28.2% | 5.75B▲ 23.8% | 4.38B▼ 23.7% | 14.96B▲ 241.1% | 4.93B▼ 67.1% | 2.58B▼ 47.7% | 5.72B▲ 122.0% | 6.4B▲ 0% |
Net Margin % | 5.08% | 11.76% | 13.76% | 23.61% | 17.76% | 51% | 16.25% | 8.21% | 17.5% | 19.19% |
Net Income Growth % | 67.98% | 136.49% | 28.21% | 23.77% | -23.73% | 241.07% | -67.05% | -47.75% | 121.98% | 86.94% |
Net Income (Continuing) | 2.17B | 4.05B | 5.27B | 5.1B | 3.52B | 4.92B | 5.31B | 2.95B | 6.29B | 6.36B |
Discontinued Operations | 0 | 0 | 0 | 1.28B | 1.58B | 10.7B | 0 | 0 | 0 | 0 |
Minority Interest | 3.56B | -688M | 9.21B | 8.5B | 8.52B | -502M | -703.69M | -585M | -420.26M | -567.04M |
EPS (Diluted) | 0.78▲ 0% | 1.82▲ 133.3% | 2.32▲ 27.5% | 2.86▲ 23.3% | 2.70▼ 5.6% | 2.40▼ 11.1% | 2.40▲ 0.0% | 1.24▼ 48.3% | 5.56▲ 348.4% | 3.14▲ 0% |
EPS Growth % | 69.57% | 133.33% | 27.47% | 23.28% | -5.59% | -11.11% | 0% | -48.33% | 348.39% | 120.34% |
EPS (Basic) | 0.78 | 1.84 | 2.34 | 2.88 | 2.74 | 2.44 | 2.44 | 1.26 | 5.64 | - |
Diluted Shares Outstanding | 1.98B | 1.99B | 2.01B | 2.02B | 1.62B | 2.04B | 2.06B | 2.07B | 1.03B | 2.04B |
Basic Shares Outstanding | 1.95B | 1.97B | 1.98B | 1.99B | 1.6B | 2.01B | 2.03B | 2.04B | 1.01B | 2.01B |
Dividend Payout Ratio | 254.96% | 108.39% | 85.1% | 69.18% | 91.2% | 28.55% | 56.68% | 94.91% | 43.87% | - |
GSK Balance Sheet
GSK plc (GSK) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 15.91B | 16.93B | 25.82B | 27.68B | 25.29B | 20.77B | 23.77B | 17B | 17.48B | 23.42B |
Cash & Short-Term Investments | 3.91B | 3.96B | 6.34B | 8.71B | 5.87B | 7.88B | 6.61B | 3.71B | 3.4B | 4.54B |
Cash Only | 3.83B | 3.87B | 6.24B | 8.6B | 5.79B | 3.72B | 3.74B | 3.69B | 3.39B | 4.54B |
Short-Term Investments | 78M | 84M | 104.66M | 106.62M | 82.62M | 4.15B | 2.86B | 21M | 8.98M | 1.32M |
Accounts Receivable | 5.69B | 6.32B | 9.47B | 9.93B | 10.88B | 6.22B | 9.44B | 6B | 7.75B | 10.47B |
Days Sales Outstanding | 68.83 | 74.87 | 102.4 | 148.82 | 160.77 | 77.4 | 113.58 | 69.79 | 86.54 | 109.31 |
Inventory | 5.56B | 5.48B | 7.88B | 8.2B | 7.83B | 5.15B | 7.01B | 5.67B | 5.91B | 8.12B |
Days Inventory Outstanding | 196.12 | 195.17 | 242.4 | 377.3 | 350.23 | 196.6 | 298.68 | 228.69 | 239.38 | 311.71 |
Other Current Assets | 1.4B | 841M | 1.71B | 352.67M | 284.43M | 1.1B | 262.61M | 1.23B | 420.26M | 295.39M |
Total Non-Current Assets | 40.47B | 41.14B | 79.75B | 82.27B | 81.85B | 39.38B | 51.45B | 42.47B | 43.53B | 59.48B |
Property, Plant & Equipment | 10.86B | 11.06B | 14.99B | 15.04B | 14.45B | 9.62B | 12.69B | 10.07B | 10.03B | 13.24B |
Fixed Asset Turnover | 2.78x | 2.79x | 2.25x | 1.62x | 1.71x | 3.05x | 2.39x | 3.11x | 3.26x | 2.64x |
Goodwill | 5.73B | 5.79B | 13.99B | 14.49B | 14.29B | 7.05B | 8.68B | 6.98B | 7.01B | 9.61B |
Intangible Assets | 17.56B | 17.2B | 41.01B | 40.77B | 40.74B | 14.32B | 18.83B | 15.52B | 16.72B | 23.92B |
Long-Term Investments | 1.02B | 1.47B | 3.18B | 4.83B | 4.29B | -2.61B | 2.73B | 1.21B | 1.12B | 5.21B |
Other Non-Current Assets | 1.5B | 1.73B | 1.15B | 1.28B | 1B | 5.35B | 808.22M | 1.93B | 2.14B | 3.11B |
Total Assets | 56.38B▲ 0% | 58.07B▲ 3.0% | 105.57B▲ 81.8% | 109.95B▲ 4.1% | 107.14B▼ 2.6% | 60.15B▼ 43.9% | 75.22B▲ 25.1% | 59.46B▼ 20.9% | 61.01B▲ 2.6% | 82.91B▲ 0% |
Asset Turnover | 0.54x | 0.53x | 0.32x | 0.22x | 0.23x | 0.49x | 0.40x | 0.53x | 0.54x | 0.43x |
Asset Growth % | -4.57% | 2.99% | 81.81% | 4.14% | -2.55% | -43.86% | 25.06% | -20.95% | 2.6% | 61.3% |
Total Current Liabilities | 26.57B | 22.49B | 31.86B | 30.28B | 32.06B | 22.81B | 26.86B | 21.7B | 21.35B | 29.58B |
Accounts Payable | 3.53B | 3.65B | 5.49B | 5.96B | 6.14B | 3.87B | 4.74B | 3.46B | 15.35B | 18.9B |
Days Payables Outstanding | 124.51 | 129.91 | 168.91 | 274.17 | 274.65 | 147.7 | 201.93 | 139.66 | 621.51 | 715.75 |
Short-Term Debt | 2.8B | 5.77B | 9.16B | 5.09B | 4.88B | 3.79B | 3.59B | 2.18B | 3.01B | 6.65B |
Deferred Revenue (Current) | 1.7B | 1.82B | 209.31M | 493.47M | 415.82M | 0 | 283.01M | 0 | 0 | 0 |
Other Current Liabilities | 12.68B | 10.52B | 14.22B | 16.03B | 17.97B | 14.1B | 15.25B | 14.76B | 2.5B | 3.29B |
Current Ratio | 0.60x | 0.75x | 0.81x | 0.91x | 0.79x | 0.91x | 0.88x | 0.78x | 0.82x | 0.79x |
Quick Ratio | 0.39x | 0.51x | 0.56x | 0.64x | 0.54x | 0.68x | 0.62x | 0.52x | 0.54x | 0.52x |
Cash Conversion Cycle | 140.44 | 140.13 | 175.89 | 251.95 | 236.35 | 126.3 | 210.33 | 158.82 | -295.6 | -294.73 |
Total Non-Current Liabilities | 26.32B | 31.9B | 49.39B | 51.23B | 46.17B | 27.24B | 32.05B | 24.68B | 23.66B | 30.35B |
Long-Term Debt | 14.22B | 20.23B | 29.91B | 30.81B | 26.76B | 16.19B | 18.04B | 13.7B | 14.68B | 18.48B |
Capital Lease Obligations | 43M | 44M | 1.34B | 1.21B | 1.1B | 841M | 1.34B | 934M | 0 | 0 |
Deferred Tax Liabilities | 1.4B | 1.16B | 5.05B | 4.92B | 4.82B | 289M | 396.46M | 382M | 290.49M | 1.73B |
Other Non-Current Liabilities | 10.56B | 10.46B | 13.06B | 14.26B | 13.38B | 9.83B | 11.95B | 9.5B | 8.69B | 11.49B |
Total Liabilities | 52.89B | 54.39B | 81.25B | 81.5B | 78.23B | 50.05B | 58.91B | 46.38B | 45.02B | 59.93B |
Total Debt | 17.09B | 26.06B | 40.42B | 37.11B | 32.74B | 20.99B | 22.97B | 16.99B | 17.69B | 25.13B |
Net Debt | 13.26B | 22.19B | 34.18B | 28.51B | 26.95B | 17.26B | 19.23B | 13.29B | 14.3B | 20.59B |
Debt / Equity | 4.90x | 7.10x | 1.66x | 1.30x | 1.13x | 2.08x | 1.41x | 1.30x | 1.11x | 1.09x |
Debt / EBITDA | 2.84x | 3.55x | 4.45x | 4.62x | 5.05x | 2.45x | 2.54x | 2.58x | 1.66x | 2.15x |
Net Debt / EBITDA | 2.21x | 3.02x | 3.76x | 3.55x | 4.16x | 2.01x | 2.13x | 2.02x | 1.34x | 1.76x |
Interest Coverage | 5.81x | 7.39x | 7.79x | 6.75x | 5.57x | 7.54x | 8.76x | 6.26x | 11.77x | 11.75x |
Total Equity | 3.49B▲ 0% | 3.67B▲ 5.2% | 24.32B▲ 562.3% | 28.44B▲ 17.0% | 28.91B▲ 1.6% | 10.1B▼ 65.1% | 16.31B▲ 61.6% | 13.09B▼ 19.8% | 15.93B▲ 21.7% | 22.97B▲ 0% |
Equity Growth % | -29.7% | 5.25% | 562.27% | 16.96% | 1.63% | -65.07% | 61.56% | -19.77% | 21.72% | 122.71% |
Book Value per Share | 1.77 | 1.85 | 12.12 | 14.11 | 17.83 | 4.94 | 7.94 | 6.32 | 15.48 | 11.28 |
Total Shareholders' Equity | -68M | 4.36B | 15.11B | 19.94B | 20.39B | 10.6B | 17.01B | 13.67B | 16.35B | 23.54B |
Common Stock | 1.34B | 1.34B | 1.78B | 1.84B | 1.82B | 1.35B | 1.72B | 1.35B | 1.35B | 1.78B |
Retained Earnings | -6.48B | -2.14B | 8.45B | 11.76B | 13.26B | 4.36B | 9.23B | 7.8B | 10.19B | 15.28B |
Treasury Stock | -400M | -161M | -178.84M | -266.56M | -37.92M | 0 | -367.14M | 0 | 0 | 0 |
Accumulated OCI | 598M | 373M | 849.16M | 2.12B | 869.56M | 0 | 2.04B | 0 | 0 | 1.86B |
Minority Interest | 3.56B | -688M | 9.21B | 8.5B | 8.52B | -502M | -703.69M | -585M | -420.26M | -567.04M |
GSK Cash Flow Statement
GSK plc (GSK) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 6.92B | 8.42B | 8.02B | 8.44B | 7.95B | 8.16B | 7.89B | 6.55B | 7.14B | 8.3B |
Operating CF Margin % | 22.92% | 27.32% | 23.76% | 34.66% | 32.2% | 27.83% | 26.02% | 20.89% | 21.87% | - |
Operating CF Growth % | 6.48% | 21.73% | -4.76% | 5.25% | -5.79% | 2.62% | -3.3% | -16.94% | 8.99% | 115.96% |
Net Income | 2.17B | 4.05B | 5.27B | 5.1B | 3.52B | 5.49B | 6.13B | 2.95B | 5.59B | 6.4B |
Depreciation & Amortization | 2.98B | 1.76B | 3B | 2.05B | 2.12B | 2.64B | 2.85B | 2.55B | 3.7B | 3.4B |
Stock-Based Compensation | 333M | 360M | 365M | 337M | 343M | 0 | 0 | 344M | 0 | 0 |
Deferred Taxes | 1.5B | 1.78B | -1.95B | 0 | 0 | -965.72M | -1.08B | 0 | 0 | 0 |
Other Non-Cash Items | 669M | 717M | 814M | -1.24B | 584M | 2.66B | 1.05B | -1.38B | -1.53B | -129.43M |
Working Capital Changes | -737M | -247M | 531M | 2.19B | 1.39B | -1.67B | -1.06B | 2.09B | -608.37M | -1.8B |
Change in Receivables | -213M | -411M | -192M | -628M | -1.16B | -758.78M | -806.74M | 340M | 0 | 0 |
Change in Inventory | -461M | 51M | 300M | 100M | 51M | -331.35M | -527.05M | -294M | 0 | 0 |
Change in Payables | 11M | 131M | 263M | 0 | 0 | 608.5M | -18.65M | 0 | 0 | 0 |
Cash from Investing | -1.44B | -1.55B | -5.35B | 2.16B | -1.78B | -10.88B | -2.4B | -1.23B | -5.72B | -6.6B |
Capital Expenditures | -2.2B | -1.8B | -2.16B | -989M | -950M | -2.78B | -2.91B | -1.4B | -2.92B | -2.68B |
CapEx % of Revenue | 7.29% | 5.83% | 6.41% | 4.06% | 3.85% | 9.48% | 9.61% | 4.46% | 8.94% | 8.04% |
Acquisitions | 356M | -292M | -3.78B | 2.85B | 185M | -3.79B | -1.72B | 1.37B | -4.37B | -5.09B |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 395M | 1.3B | 846M | -2.97B | -1.03B | -4.43B | 14.92M | -1.22B | 1.46B | 996.88M |
Cash from Financing | -6.38B | -6.39B | -1.84B | -10.13B | -7.59B | 2.05B | -6.07B | -4.73B | -1.59B | -3B |
Debt Issued (Net) | -990M | 8.15B | 3.73B | -4.03B | -2B | -5.69B | -2.95B | -1.17B | 1.47B | 141.62M |
Equity Issued (Net) | -9M | 74M | 51M | 29M | 21M | 30.79M | 12.43M | 20M | 14.67M | -1.33B |
Dividends Paid | -3.91B | -3.93B | -3.95B | -3.98B | -4B | -4.27B | -2.79B | -2.44B | -2.51B | -2.83B |
Share Repurchases | -65M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1.34B |
Other Financing | -1.48B | -10.69B | -1.67B | -2.15B | -1.61B | 11.98B | -341.84M | -1.14B | -573.16M | 1.02B |
Net Change in Cash | -1B▲ 0% | 487M▲ 148.5% | 744M▲ 52.8% | 431M▼ 42.1% | -1.44B▼ 434.8% | -1.31B▲ 9.2% | -735.58M▲ 43.9% | 545M▲ 174.1% | -206.06M▼ 137.8% | -1.37B▲ 0% |
Free Cash Flow | 4.72B▲ 0% | 6.63B▲ 40.5% | 5.86B▼ 11.6% | 6.5B▲ 10.9% | 5.3B▼ 18.4% | 6.75B▲ 27.5% | 6.26B▼ 7.3% | 3.57B▼ 42.9% | 5.82B▲ 63.1% | 7.37B▲ 0% |
FCF Margin % | 15.62% | 21.5% | 17.35% | 26.67% | 21.45% | 23.03% | 20.63% | 11.38% | 17.83% | 22.11% |
FCF Growth % | 13.78% | 40.48% | -11.59% | 10.91% | -18.44% | 27.46% | -7.33% | -42.92% | 63.06% | 58% |
FCF per Share | 2.39 | 3.33 | 2.92 | 3.22 | 3.27 | 3.31 | 3.04 | 1.72 | 5.66 | 3.62 |
FCF Conversion (FCF/Net Income) | 4.52x | 2.32x | 1.73x | 1.47x | 1.81x | 0.55x | 1.60x | 2.55x | 1.25x | 1.15x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
GSK Key Ratios
GSK plc (GSK) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | 36.25% | 101.19% | 33.19% | 21.79% | 15.29% | 76.69% | 37.32% | 17.52% | 39.4% | 31.48% |
Return on Invested Capital (ROIC) | 17.22% | 19.3% | 12.38% | 7.77% | 5.79% | 11.6% | 16.09% | 9.74% | 22.1% | 17.62% |
Gross Margin | 65.74% | 66.77% | 64.85% | 67.44% | 66.95% | 67.42% | 71.76% | 71.16% | 72.4% | 72.86% |
Net Margin | 5.08% | 11.76% | 13.76% | 23.61% | 17.76% | 51% | 16.25% | 8.21% | 17.5% | 19.19% |
Debt / Equity | 4.90x | 7.10x | 1.66x | 1.30x | 1.13x | 2.08x | 1.41x | 1.30x | 1.11x | 1.09x |
Interest Coverage | 5.81x | 7.39x | 7.79x | 6.75x | 5.57x | 7.54x | 8.76x | 6.26x | 11.77x | 11.75x |
FCF Conversion | 4.52x | 2.32x | 1.73x | 1.47x | 1.81x | 0.55x | 1.60x | 2.55x | 1.25x | 1.15x |
Revenue Growth | 8.24% | 2.1% | 9.52% | -27.85% | 1.4% | 18.74% | 3.42% | 3.46% | 4.11% | 5.41% |
Related:GSK Dividend History·GSK Revenue History·GSK Price History·GSK P/E History·GSK Financial Ratios·GSK Institutional Holders
GSK Frequently Asked Questions
GSK plc (GSK) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
GSK plc (GSK) reported $33.34B in revenue for fiscal year 2025. This represents a 300% increase from $8.34B in 1996.
GSK plc (GSK) grew revenue by 4.1% over the past year. Growth has been modest.
Yes, GSK plc (GSK) is profitable, generating $6.40B in net income for fiscal year 2025 (17.5% net margin).
Dividend & Returns
Yes, GSK plc (GSK) pays a dividend with a yield of 6.39%. This makes it attractive for income-focused investors.
GSK plc (GSK) has a return on equity (ROE) of 39.4%. This is excellent, indicating efficient use of shareholder capital.
GSK plc (GSK) generated $7.37B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.